BACKGROUND: Phenylacetic acid (PAA) is the active moiety in sodium phenylbutyrate (NaPBA) and glycerol phenylbutyrate (GPB, HPN-100). Both are approved for treatment of urea cycle disorders (UCDs) - rare genetic disorders characterized by hyperammonemia. PAA is conjugated with glutamine in the liver to form phenylacetyleglutamine (PAGN), which is excreted in urine. PAA plasma levels ≥ 500 μg/dL have been reported to be associated with reversible neurological adverse events (AEs) in cancer patients receiving PAA intravenously. Therefore, we have investigated the relationship between PAA levels and neurological AEs in patients treated with these PAA pro-drugs as well as approaches to identifying patients most likely to experience high PAA levels. METHODS: The relationship between nervous system AEs, PAA levels and the ratio of plasma PAA to PAGN were examined in 4683 blood samples taken serially from: [1] healthy adults [2], UCD patients of ≥ 2 months of age, and [3] patients with cirrhosis and hepatic encephalopathy (HE). The plasma ratio of PAA to PAGN was analyzed with respect to its utility in identifying patients at risk of high PAA values. RESULTS: Only 0.2% (11) of 4683 samples exceeded 500 μg/ml. There was no relationship between neurological AEs and PAA levels in UCD or HE patients, but transient AEs including headache and nausea that correlated with PAA levels were observed in healthy adults. Irrespective of population, a curvilinear relationship was observed between PAA levels and the plasma PAA:PAGN ratio, and a ratio>2.5 (both in μg/mL) in a random blood draw identified patients at risk for PAA levels>500 μg/ml. CONCLUSIONS: The presence of a relationship between PAA levels and reversible AEs in healthy adults but not in UCD or HE patients may reflect intrinsic differences among the populations and/or metabolic adaptation with continued dosing. The plasma PAA:PAGN ratio is a functional measure of the rate of PAA metabolism and represents a useful dosing biomarker.
BACKGROUND:Phenylacetic acid (PAA) is the active moiety in sodium phenylbutyrate (NaPBA) and glycerol phenylbutyrate (GPB, HPN-100). Both are approved for treatment of urea cycle disorders (UCDs) - rare genetic disorders characterized by hyperammonemia. PAA is conjugated with glutamine in the liver to form phenylacetyleglutamine (PAGN), which is excreted in urine. PAA plasma levels ≥ 500 μg/dL have been reported to be associated with reversible neurological adverse events (AEs) in cancerpatients receiving PAA intravenously. Therefore, we have investigated the relationship between PAA levels and neurological AEs in patients treated with these PAA pro-drugs as well as approaches to identifying patients most likely to experience high PAA levels. METHODS: The relationship between nervous system AEs, PAA levels and the ratio of plasma PAA to PAGN were examined in 4683 blood samples taken serially from: [1] healthy adults [2], UCD patients of ≥ 2 months of age, and [3] patients with cirrhosis and hepatic encephalopathy (HE). The plasma ratio of PAA to PAGN was analyzed with respect to its utility in identifying patients at risk of high PAA values. RESULTS: Only 0.2% (11) of 4683 samples exceeded 500 μg/ml. There was no relationship between neurological AEs and PAA levels in UCD or HEpatients, but transient AEs including headache and nausea that correlated with PAA levels were observed in healthy adults. Irrespective of population, a curvilinear relationship was observed between PAA levels and the plasma PAA:PAGN ratio, and a ratio>2.5 (both in μg/mL) in a random blood draw identified patients at risk for PAA levels>500 μg/ml. CONCLUSIONS: The presence of a relationship between PAA levels and reversible AEs in healthy adults but not in UCD or HEpatients may reflect intrinsic differences among the populations and/or metabolic adaptation with continued dosing. The plasma PAA:PAGN ratio is a functional measure of the rate of PAA metabolism and represents a useful dosing biomarker.
Keywords:
BUPHENYL; GEE; GPB; Glycerol phenylbutyrate; HE; HPN-100; NaPBA; Neurological adverse events; PAA; PAA:PAGN ratio; PAGN; PBA; RAVICTI; SE; SO; Sodium phenylbutyrate; UCD; generalized estimating equations; glycerol phenylbutyrate (generic name for glyceryl tri (4-phenylbutyrate), also referred to as HPN-100 or RAVICTI(®)); hepatic encephalopathy; phenylacetic acid; phenylacetylglutamine; phenylbutyric acid; ratio of the concentrations in μg/mL of PAA to PAGN in plasma; safety extension; sodium phenylbutyrate (BUPHENYL(®)); switchover; urea cycle disorder
Authors: Luis H Camacho; Jon Olson; William P Tong; Charles W Young; David R Spriggs; Mark G Malkin Journal: Invest New Drugs Date: 2006-10-20 Impact factor: 3.850
Authors: S M Chang; J G Kuhn; H I Robins; S C Schold; A M Spence; M S Berger; M P Mehta; M E Bozik; I Pollack; D Schiff; M Gilbert; C Rankin; M D Prados Journal: J Clin Oncol Date: 1999-03 Impact factor: 44.544
Authors: Gregory M Enns; Susan A Berry; Gerard T Berry; William J Rhead; Saul W Brusilow; Ada Hamosh Journal: N Engl J Med Date: 2007-05-31 Impact factor: 91.245
Authors: A Thibault; D Samid; M R Cooper; W D Figg; A C Tompkins; N Patronas; D J Headlee; D R Kohler; D J Venzon; C E Myers Journal: Cancer Date: 1995-06-15 Impact factor: 6.860
Authors: R Todd Stravitz; Michelle Gottfried; Valerie Durkalski; Robert J Fontana; A James Hanje; David Koch; Bilal Hameed; Daniel Ganger; Ram M Subramanian; Stan Bukofzer; William R Ravis; Kristen Clasen; Averell Sherker; Lanna Little; William M Lee Journal: Hepatology Date: 2018-01-30 Impact factor: 17.425
Authors: M Mokhtarani; G A Diaz; U Lichter-Konecki; S A Berry; J Bartley; S E McCandless; W Smith; C Harding; C Le Mons; D F Coakley; B Lee; B F Scharschmidt Journal: Mol Genet Metab Rep Date: 2015-09-27
Authors: Meritxell Ventura-Cots; Mar Concepción; José Antonio Arranz; Macarena Simón-Talero; Maria Torrens; Albert Blanco-Grau; Inma Fuentes; Pilar Suñé; Edilmar Alvarado-Tapias; Cristina Gely; Eva Roman; Beatriz Mínguez; German Soriano; Joan Genescà; Juan Córdoba Journal: Therap Adv Gastroenterol Date: 2016-07-26 Impact factor: 4.409
Authors: B Lee; G A Diaz; W Rhead; U Lichter-Konecki; A Feigenbaum; S A Berry; C Le Mons; J Bartley; N Longo; S C Nagamani; W Berquist; R C Gallagher; C O Harding; S E McCandless; W Smith; A Schulze; M Marino; R Rowell; D F Coakley; M Mokhtarani; B F Scharschmidt Journal: Mol Genet Metab Date: 2015-11-11 Impact factor: 4.797
Authors: Brendan Lee; George A Diaz; William Rhead; Uta Lichter-Konecki; Annette Feigenbaum; Susan A Berry; Cindy Le Mons; James A Bartley; Nicola Longo; Sandesh C Nagamani; William Berquist; Renata Gallagher; Dennis Bartholomew; Cary O Harding; Mark S Korson; Shawn E McCandless; Wendy Smith; Stephen Cederbaum; Derek Wong; J Lawrence Merritt; Andreas Schulze; Jerry Vockley; Gerard Vockley; David Kronn; Roberto Zori; Marshall Summar; Douglas A Milikien; Miguel Marino; Dion F Coakley; Masoud Mokhtarani; Bruce F Scharschmidt Journal: Genet Med Date: 2014-12-11 Impact factor: 8.822